DAVID GRAY & CO. PTY LIMITED
2 Rawlinson Street O'CONNOR WA 6163
PO BOX 2084 PALMYRA DC WA 6961
Ph: (08) 9337 4933; Fax: (08) 9337 8316
email: general@davidgray.com.au
web: www.davidgray.com.au

SAFETY DATA SHEET

PRODUCT NAME **DAVID GRAYS POULTRY DUST**

1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

Supplier name	**DAVID GRAY & CO PTY LIMITED**
Address	2 Rawlinson St, O'Connor, WA, 6961, AUSTRALIA
Telephone	(08) 9337 4933
Fax	(08) 9337 8316
Emergency	(08) 9337 4933 (B/H)
Email	general@davidgray.com.au
Web site	http://www.davidgray.com.au
Synonym(s)	24763 (15KG) ● MANUFACTURER'S CODE: 3548 (12X400G), 24711 (3KG) ● POULTRY DUST
Use(s)	INSECT CONTROL ● USED TO CONTROL FLEAS, FLIES, LICE, TICKS & MITES ON POULTRY
SDS date	18 April 2018

2. HAZARDS IDENTIFICATION

CLASSIFIED AS HAZARDOUS ACCORDING TO SAFE WORK AUSTRALIA CRITERIA

Risk Phrases

R43	May cause sensitisation by skin contact.

Safety Phrases

S22	Do not breathe dust.
S24	Avoid contact with skin.
S37	Wear suitable gloves.
S46	If swallowed, contact a doctor or Poisons Information Centre immediately and show container or label.

NOT CLASSIFIED AS A DANGEROUS GOOD BY THE CRITERIA OF THE ADG CODE

UN Number	None Allocated	**Transport Hazard Class**	None Allocated
Packing Group	None Allocated	**Hazchem Code**	None Allocated

3. COMPOSITION/ INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EC Number	Content
MALATHION	121-75-5	204-497-7	2%
FILLER(S)	-	-	98%

4. FIRST AID MEASURES

Eye	If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.
Inhalation	If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
Skin	If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.
Ingestion	For advice, contact a Poisons Information Centre on 13 11 26 (Australia Wide) or a doctor (at once). If swallowed, do not induce vomiting.
Advice to doctor	This product is a cholinesterase inhibitor affecting the nervous system and producing cardiac and respiratory depression. Administer atropine sulphate. The dose and the frequency of atropine will vary with each patient, but the patient should remain fully atropinised. In severe cases pralidoxime

Advice to doctor

may be administered as well, if given within 24 hours after exposure. Artificial respiration or oxygen may be necessary. Monitor respiratory, cardiac and central nervous system function. Also monitor red blood cell and plasma cholinesterase levels. Watch for pulmonary oedema and delayed neurological symptoms.

Contraindications - Morphine, barbiturates, phenothiazine derivatives, tranquillisers, and all kinds of central nervous system stimulants are contraindicated. Also, large amounts of intravenous fluids are generally contraindicated because of the threat of pulmonary oedema.

First aid facilities Eye wash facilities and safety shower should be available.

5. FIRE FIGHTING MEASURES

Flammability Non flammable. May evolve toxic gases (carbon/ sulphur/ phosphorus/ nitrogen oxides) when heated to decomposition.

Fire and explosion Evacuate area and contact emergency services. Toxic gases may be evolved in a fire situation. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

Extinguishing Use an extinguishing agent suitable for the surrounding fire.

Hazchem code None allocated.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

Environmental precautions Prevent product from entering drains and waterways.

Methods of cleaning up Contain spillage, then collect and place in suitable containers for disposal. Avoid generating dust. For small spills, wear required protective equipment, then sweep up, contain and reuse spilt product. Wash contaminated surfaces with a mild bleach solution.

References See Sections 8 and 13 for exposure controls and disposal.

7. STORAGE AND HANDLING

Storage Store in a cool, dry, well ventilated area, removed from moisture, incompatible substances, heat or ignition sources and foodstuffs. Ensure containers are adequately labelled, protected from physical damage and sealed when not in use. Large storage areas should have appropriate fire protection systems.

Handling Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas (e.g. if container is damaged). Use only according to the label directions.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure standards

Ingredient	Reference	TWA		STEL	
		ppm	mg/m³	ppm	mg/m³
Malathion	SWA (AUS)	--	10	--	--

Biological limits

Ingredient	Determinant	Sampling Time	BEI
MALATHION	Cholinesterase activity in red blood cells	Discretionary	70% of individual's baseline

Reference: ACGIH Biological Exposure Indices

Engineering controls Avoid inhalation. Use in well ventilated areas. Maintain dust levels below the recommended exposure standard.

PPE

Eye / Face	Wear dust-proof goggles.
Hands	Wear PVC or rubber gloves.
Body	When using large quantities or where heavy contamination is likely, wear coveralls.
Respiratory	Where an inhalation risk exists, wear a Class P1 (Particulate) respirator.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	LIGHT CREAM COLOURED DUST
Odour	SLIGHT ODOUR
Flammability	NON FLAMMABLE
Flash point	NOT RELEVANT
Boiling point	NOT AVAILABLE
Melting point	NOT AVAILABLE
Evaporation rate	NOT AVAILABLE
pH	NOT AVAILABLE
Vapour density	NOT AVAILABLE
Specific gravity	NOT AVAILABLE
Solubility (water)	INSOLUBLE
Vapour pressure	NOT AVAILABLE
Upper explosion limit	NOT RELEVANT
Lower explosion limit	NOT RELEVANT
Partition coefficient	NOT AVAILABLE
Autoignition temperature	NOT AVAILABLE
Decomposition temperature	NOT AVAILABLE
Viscosity	NOT AVAILABLE
Explosive properties	NOT AVAILABLE
Oxidising properties	NOT AVAILABLE
Odour threshold	NOT AVAILABLE

10. STABILITY AND REACTIVITY

Chemical stability	Stable under recommended conditions of storage.
Conditions to avoid	Avoid heat, sparks, open flames and other ignition sources.
Material to avoid	Incompatible with oxidising agents (e.g. hypochlorites), acids (e.g. nitric acid), alkalis (e.g. sodium hydroxide), iron, zinc, stainless/galvanised steel and heat sources.
Hazardous Decomposition Products	May evolve toxic gases (carbon/ sulphur/ phosphorus/ nitrogen oxides) when heated to decomposition.
Hazardous Reactions	Polymerization is not expected to occur.

11. TOXICOLOGICAL INFORMATION

Health Hazard Summary	Harmful. Use safe work practices to avoid eye or skin contact and inhalation. Cholinesterase inhibitor resulting in the accumulation of acetylcholine, causing rapid twitching of voluntary muscles and finally paralysis. Symptoms may include headaches, dizziness, nausea, diarrhoea, muscle twitching, tremors, abdominal cramps, tightness in chest, sweating, blurred vision, salivation, excessive urination and convulsions. Symptoms are often characterised as short acting yet having complete and rapid reversibility. No adverse health effects are expected when the product is used in accordance with label directions.
Eye	Irritant. Contact may result in irritation, lacrimation, pain, redness and blurring or dimness of vision.
Inhalation	Irritant. Over exposure to dust may result in irritation of the nose and throat, coughing, weakness, nausea, vomiting and diarrhoea. High level exposure may result in dizziness, incoordination, excessive salivation, sweating, and breathing difficulties. Cholinesterase inhibitor.
Skin	Irritant. Contact may result in irritation, redness, pain and rash. May be absorbed through skin with

Skin

harmful effects. May cause sensitisation by skin contact. LD50 > 102500 mg/kg.

Ingestion May be harmful. Ingestion may result in nausea, vomiting, abdominal pain, diarrhoea, fatigue, and sweating and/or salivation. Ingestion of large quantities may result in breathing difficulties, muscle spasms and convulsions. Oral LD50 (rat) is > 70000 mg/kg.

Toxicity data MALATHION (121-75-5)

LD50 (oral)	190 mg/kg (mouse)
LD50 (dermal)	2330 mg/kg (mouse)
LC50 (inhalation)	43790 ug/m³/4hrs (rat)

12. ECOLOGICAL INFORMATION

Toxicity No information provided.

Persistence and degradability No information provided.

Bioaccumulative potential No information provided.

Mobility in soil No information provided.

Other adverse effects No information provided.

13. DISPOSAL CONSIDERATIONS

Waste disposal For small amounts, the best way of disposing of the product is to use in accordance with the original label directions. Contact the manufacturer/supplier for additional information if disposing of large quantities (if required). Empty containers should be disposed of by wrapping in paper, placing in a plastic bag and putting in the garbage. Empty containers should not be burned. For domestic packs, dispose of empty containers by wrapping in paper, placing in a plastic bag and putting in the rubbish.

Legislation Dispose of in accordance with relevant local legislation.

14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD BY THE CRITERIA OF THE ADG CODE, IMDG OR IATA

	LAND TRANSPORT (ADG)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
UN Number	None Allocated	None Allocated	None Allocated
Proper Shipping Name	None Allocated	None Allocated	None Allocated
Transport Hazard Class	None Allocated	None Allocated	None Allocated
Packing Group	None Allocated	None Allocated	None Allocated

Environmental hazards No information provided

Special precautions for user

Hazchem code None Allocated

15. REGULATORY INFORMATION

Poison schedule Classified as a Schedule 5 (S5) Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).

Inventory Listing(s) **AUSTRALIA: AICS (Australian Inventory of Chemical Substances)**
All components are listed on AICS, or are exempt.

16. OTHER INFORMATION

Additional information

PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:
The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:
It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

Abbreviations

ACGIH	American Conference of Governmental Industrial Hygienists
CAS #	Chemical Abstract Service number - used to uniquely identify chemical compounds
CNS	Central Nervous System
EC No.	EC No - European Community Number
EMS	Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous Goods)
GHS	Globally Harmonized System
GTEPG	Group Text Emergency Procedure Guide
IARC	International Agency for Research on Cancer
LC50	Lethal Concentration, 50% / Median Lethal Concentration
LD50	Lethal Dose, 50% / Median Lethal Dose
mg/m³	Milligrams per Cubic Metre
OEL	Occupational Exposure Limit
pH	relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly alkaline).
ppm	Parts Per Million
STEL	Short-Term Exposure Limit
STOT-RE	Specific target organ toxicity (repeated exposure)
STOT-SE	Specific target organ toxicity (single exposure)
SUSMP	Standard for the Uniform Scheduling of Medicines and Poisons
SWA	Safe Work Australia
TLV	Threshold Limit Value
TWA	Time Weighted Average

Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

Prepared by

Risk Management Technologies
5 Ventnor Ave, West Perth
Western Australia 6005
Phone: +61 8 9322 1711
Fax: +61 8 9322 1794
Email: info@rmt.com.au
Web: www.rmtglobal.com

[End of SDS]